M2I-1 disrupts the in vivo interaction between CDC20 and MAD2 and increases the sensitivities of cancer cell lines to anti-mitotic drugs via MCL-1s

M2I-1 disrupts the in vivo interaction between CDC20 and MAD2 and increases the sensitivities of cancer cell lines to anti-mitotic drugs via MCL-1s

Abstract Background Drugs such as taxanes, epothilones, and vinca alkaloids are widely used in the treatment of breast, ovarian, and lung cancers but come with major side effects such as neuropathy and loss of neutrophils and as single agents have a lack of efficacy. M2I-1 (MAD2 inhibitor-1) has bee...

Full description

Bibliographic Details
Main Authors: Jianquan Li, Nanmao Dang, Nuria Martinez-Lopez, Paul A. Jowsey, Dong Huang, Robert N. Lightowlers, Fei Gao, Jun-Yong Huang
Format: Article
Language:English
Published: BMC 2019-06-01
Series:Cell Division
Subjects:
M2I-1
Cyclin B1
MCL-1
Nocodazole
Taxol
Apoptosis
Online Access:http://link.springer.com/article/10.1186/s13008-019-0049-5

Internet

http://link.springer.com/article/10.1186/s13008-019-0049-5

Similar Items